Zentalis Pharmaceuticals (ZNTL) Total Current Liabilities (2019 - 2026)

Zentalis Pharmaceuticals' Total Current Liabilities history runs 8 years deep, the most recent figure standing at $35.2 million for Q1 2026.

• On a quarterly basis, Total Current Liabilities fell 28.72% year-over-year to $35.2 million in Q1 2026; TTM through Mar 2026 was $35.2 million, a 28.72% decrease from a year earlier, with the FY2025 full-year figure at $36.6 million, down 30.66% from the prior year.
• Total Current Liabilities retreated to $35.2 million in Q1 2026 per ZNTL's latest filing, from $36.6 million in the prior quarter.
• Across five years, Total Current Liabilities topped out at $69.4 million in Q4 2023 and bottomed at $35.2 million in Q1 2026.
• The 5-year median for Total Current Liabilities is $52.7 million (2024), against an average of $50.9 million.
• Across the five-year window, Total Current Liabilities jumped 44.85% in 2022 and plunged 41.49% in 2025, its largest moves.
• Year by year, Total Current Liabilities stood at $56.6 million in 2022, then gained by 22.45% to $69.4 million in 2023, then fell by 23.99% to $52.7 million in 2024, then tumbled by 30.66% to $36.6 million in 2025, then slipped by 3.62% to $35.2 million in 2026.
• Per Business Quant, the three latest ZNTL Total Current Liabilities figures stand at $35.2 million (Q1 2026), $36.6 million (Q4 2025), and $37.2 million (Q3 2025).